Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Advertisement
Katy MarshallTesticular, Penile, and Rare Malignancies | February 22, 2024
Researchers analyzed the data of patients with locally advanced PSCC and clinical lymph node metastasis.
Read More
Emily MenendezTesticular, Penile, and Rare Malignancies | February 12, 2024
The use of surveillance with repeat CT scans can accurately identify patients with true CS I.
Katy MarshallASCO GU Symposium 2024 | January 24, 2024
The retrospective analysis evaluated 145 plasma samples from 35 patients with stage I, II, and III testicular cancer.
Katy MarshallTesticular, Penile, and Rare Malignancies | January 5, 2024
The updated guidelines include strong, moderate, and conditional recommendations for clinicians.
Leah LawrenceTesticular, Penile, and Rare Malignancies | February 2, 2024
Testicular cancer experts discuss current practices and challenges related to staging, treatment, and survivorship.
Katy MarshallTesticular, Penile, and Rare Malignancies | December 21, 2023
Researchers reviewed data from patients with testicular cancer between 2003 and 2020, including orchiectomy patients.
Zachary BessetteSUO 2023 | December 18, 2023
Drs. Pierorazio and Eggener moderated a session on simultaneous optimization of organ transplant and GU cancer outcomes.
Zachary BessetteSUO 2023 | January 11, 2024
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | October 30, 2023
From presentation with a testicular mass to treatment options, this provides valuable insights for community oncologists.
Thomas Wagner, MDTesticular, Penile, and Rare Malignancies | October 27, 2023
Dr. Wagner details his study on finding novel prognostic factors for relapse in patients with stage I testicular seminoma.
Aditya Bagrodia, MD, FACSTesticular, Penile, and Rare Malignancies | October 6, 2023
Drs. Bagrodia and Ambinder provide an overview of the care continuum for newly diagnosed testicular cancer patients.
Aditya Bagrodia, MD, FACSTesticular, Penile, and Rare Malignancies | October 6, 2023
Drs. Bagrodia and Ambinder walk through a community urologist's approach to a patient who presents with a testicular mass.
Emily MenendezTesticular, Penile, and Rare Malignancies | September 25, 2023
Patients with a complete resection at pcRPLND and <10% viable cells had favorable outcomes without any further treatment.
Emily MenendezTesticular, Penile, and Rare Malignancies | September 15, 2023
The AUA released a new amendment to their 2019 guideline for the diagnosis and treatment of early-stage testicular cancer.
Emily MenendezTesticular, Penile, and Rare Malignancies | September 13, 2023
Newly identified risk factors could be used in future studies on risk-adapted follow-up and treatment strategies.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | September 1, 2023
Unique characteristics include higher stage at presentation and a more aggressive subsequent clinical course.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | September 1, 2023
It may be time to include RPLND for patients with retroperitoneal disease following treatment for seminoma.
Emily MenendezTesticular, Penile, and Rare Malignancies | August 4, 2023
Is atezolizumab plus radiotherapy or atezolizumab monotherapy more effective for advanced penile cancer?
Emily MenendezTesticular, Penile, and Rare Malignancies | June 26, 2023
As chemotherapy and radiotherapy can negatively impact the QOL of cancer survivors, RPLND offers less burden to patients.
Emily MenendezTesticular, Penile, and Rare Malignancies | April 28, 2023
TC treatment, especially platinum-based chemotherapy, is associated with an increased risk of cardiovascular morbidity.
Advertisement
Advertisement
Advertisement